ANDA 86761, held by Abraxis Pharm. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 86761 (Lidocaine Hydrochloride), held by Abraxis Pharm, was first approved by FDA on Dec 14, 1979, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 14, 1979 | Original application | Approved | None posted |
| Lidocaine Hydrochloride1% · injectable;injection | Lidocaine Hydrochloride | Discontinued |
| Lidocaine Hydrochloride2% · injectable;injection | Lidocaine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters